HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 280, Issue 40, 33735-33738, October 7, 2005

This Article Abstract Full Text (PDF) All Versions of this Article: 280/40/33735    most recent M506485200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lahiri, S. Articles by Futerman, A. H. Search for Related Content PubMed PubMed Citation Articles by Lahiri, S. Articles by Futerman, A. H. Social Bookmarking                      What's this?

LASS5 Is a Bona Fide Dihydroceramide Synthase That Selectively Utilizes Palmitoyl-CoA as Acyl Donor^*

From the Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel

Received for publication, June 14, 2005

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
We demonstrated recently (Riebeling, C., Allegood, J.C., Wang, E., Merrill, A. H. Jr., and Futerman, A. H. (2003) J. Biol. Chem. 278, 43452–43459) that upon over-expression in human embryonic kidney cells, longevity assurance gene homolog 5 (LASS5, previously named TRH4) elevates the synthesis of (dihydro)ceramides selectively enriched in palmitic acid. To determine whether LASS5 is a bona fide dihydroceramide synthase or, alternatively, whether it modifies an endogenous dihydroceramide synthase, we over-expressed LASS5 with a hemagglutinin (HA) tag at the C terminus, solubilized it using digitonin, and purified it by immunoprecipitation. Solubilized LASS5-HA displays the same fatty acid selectivity as the membrane-bound enzyme. After elution from agarose beads, only one band could be detected by SDS-PAGE, and its identity was confirmed to be LASS5 by mass spectrometry. Dihydroceramide synthase activity of the eluted LASS5-HA protein was totally dependent on exogenously added phospholipids. Moreover, eluted LASS5-HA was highly selective toward palmitoyl-CoA as acyl donor and was inhibited by the (dihydro)ceramide synthase inhibitor, fumonisin B1. This study identifies LASS5 as a genuine dihydroceramide synthase and demonstrates that mammalian dihydroceramide synthases do not require additional subunits for their activity.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Ceramide, an important lipid second messenger (1–3), consists of a sphingoid long chain base to which a fatty acid is attached at carbon-2 via an amide bond. Ceramide is also a key metabolite in the pathway of sphingolipid (SL)² biosynthesis (4), and within the past 2–3 years the molecular identities of most of the enzymes in this pathway have been identified (5). Among these, a family of mammalian genes that regulates ceramide synthesis has been discovered (6, 7). Surprisingly, over-expression of each of these genes in various mammalian cells leads to an increase in ceramides containing different fatty acids (8–10). Thus, over-expression of LASS1 leads to an increase in the synthesis of ceramides containing stearic acid (8), whereas over-expression of LASS5 leads to an increase of ceramide containing palmitic acid (9). However, it is not known whether these genes modify an endogenous ceramide synthase activity, and thereby confer fatty acid selectivity, or whether the LASS proteins themselves are bona fide dihydroceramide synthases.

We have now purified, by immunoprecipitation, LASS5 with an HA tag at the C terminus and demonstrate here that it is a genuine dihydroceramide synthase that displays the same fatty acid selectivity as seen upon its over-expression in mammalian cells. This is the first biochemical isolation of a mammalian dihydroceramide synthase and paves the way for studying the role of LASS proteins in regulating ceramide production both for SL biosynthesis and for the regulation of the defined aspects of cell physiology in which it plays vital roles.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Materials—1-[¹⁴C]Palmitoyl-CoA (specific activity, 60 mCi/mmol) was from Amersham Biosciences, and 1-[¹⁴C]stearoyl-CoA (specific activity, 55 mCi/mmol) was from American Radiolabeled Chemicals (St. Louis, MO). Fumonisin B1, defatted bovine serum albumin, phenylmethylsulfonyl fluoride, leupeptin, antipain, and aprotinin were from Sigma. Sphinganine, sphingosine, palmitoylsphingosine, and stearoylsphingosine were from Matreya (Pleasant Gap, PA). Digitonin was from Sigma or Calbiochem. A monoclonal anti-HA-agarose conjugate (clone HA-7) was from Sigma, a rabbit polyclonal anti-HA antibody (Y-11) and protein A-agarose were from Santa Cruz Biotechnology (Santa Cruz, CA), and peroxidase-conjugated AffiniPure goat anti-mouse IgG was from Jackson ImmunoResearch Laboratories (West Grove, PA). Dioleoylphosphatidylcholine (DOPC) and dioleoylphosphatidylserine (DOPS) were from Avanti%20Polar%20Lipids">Avanti Polar Lipids (Alabaster, AL). Silica gel 60 TLC plates were from Merck. All solvents were of analytical grade and were purchased from Biolab (Jerusalem, Israel).

Cell Culture and Transfection—Human embryonic kidney 293T cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 100 IU/ml penicillin, and 100 µg/ml streptomycin. Transfections using LASS5-HA (9) were performed by the calcium phosphate method. Transfections were also performed with pcDNA-HA as a control.

Solubilization of LASS5-HA—293T cells, at 90% confluency, were washed with phosphate-buffered saline and removed from culture dishes using trypsin (0.05%, w/v). After centrifugation (4 min, 150 x g_av) cell pellets were washed twice with phosphate-buffered saline by centrifugation (4 min, 150 x g_av) and then homogenized in 20 mM HEPES-KOH, pH 7.4, 25 mM KCl, 250 mM sucrose, and 2 mM MgCl₂ containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, 1 µg/ml antipain, and 100 kallikrein-inactivating units/ml aprotinin). Digitonin was added to the homogenate to give a final concentration of 1% (w/v), and after 1 h at 4°C, the homogenate was centrifuged at 100,000 x g_av for 30 min. The resulting supernatant was used for subsequent purification steps.

Immunoprecipitation of LASS5-HA—The digitonin-solubilized supernatant was concentrated using an iCON concentrator (Pierce) and then incubated with protein A-agarose for 1 h at 4 °C to reduce nonspecific binding. After removal of protein A-agarose by centrifugation, the supernatant was incubated with an anti-HA agarose conjugate overnight at 4 °C. The conjugate was then pelleted by centrifugation and washed with the same HEPES buffer used for homogenization followed by a wash with 1 M NaCl. LASS5-HA was eluted from the beads using 100 mM glycine, pH 2.5, and immediately neutralized using 1 M Trizma (Tris base), pH 11. The eluate was concentrated using an iCON concentrator, and in some cases, DOPC or DOPS liposomes prepared as described (11), were added to the concentrated eluate prior to analysis of dihydroceramide synthase activity. The composition of the eluate was analyzed by SDS-polyacrylamide gel electrophoresis (10% polyacrylamide gel) and Western blotting using a rabbit polyclonal anti-HA antibody. Control immunoprecipitations were performed using cells that had been transfected with pcDNA-HA.

Mass Spectrometry—Protein bands were excised from the SDS gel and subsequently reduced, alkylated, and in-gel-digested for 18 h with bovine trypsin (sequencing grade, Roche Diagnostics) at a concentration of 12.5 ng/µl in 50 mM ammonium bicarbonate at 37 °C. An extracted peptide solution was dried for subsequent matrix-assisted laser desorption/time of flight ionization (MALDI-TOF) and electrospray ionization mass spectrometric analyses.

Aliquots of the extracted peptide mixture and electroeluted proteins, dissolved in 0.1% trifluoroacetic acid or a mixture of formic acid/isopropanol/H₂0 (1/3/2; v/v/v), were used for MALDI-TOF mass spectrometry. Peptide fingerprinting was performed on a Bruker Reflex III^TM MALDI-TOF mass spectrometer (Bruker, Bremen, Germany) equipped with a delayed extraction ion source, a reflector, and a 337-nm nitrogen laser.

Dihydroceramide Synthase Assay—For cell fractions, 500 µg of protein (determined using BCA reagent (Pierce)) was incubated with 15 µM sphinganine and 20 µM defatted bovine serum albumin (12) for 5 min at 37 °C with or without fumonisin B1 (20 µM), and the reaction was initiated by the addition of either 0.12 µCi of 1-[¹⁴C]palmitoyl-CoA or 0.12 µCi of 1-[¹⁴C]stearoyl-CoA for a further 20 min (9). When immunoprecipitated LASS5-HA was assayed, either sphinganine or sphingosine was used as long chain base, and the reaction time was 1 h. Lipids were extracted and levels of dihydroceramide synthesis analyzed by thin layer chromatography using chloroform/methanol/2 M ammonium hydroxide (40/10/1; v/v/v) as the developing solvent and using palmitoylsphingosine and stearoylsphingosine as standards. Lipids were visualized using a phosphorimaging screen (Fuji, Tokyo, Japan), recovered from TLC plates by scraping the silica directly into scintillation vials, and quantified by liquid scintillation counting.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Initial experiments were performed to establish a means to solubilize membrane-bound LASS5-HA. Digitonin, which was previously used to solubilize Lag1p (13), a yeast LASS homolog (14, 15), was able to solubilize LASS5-HA and preserve dihydroceramide synthase activity. Most of the dihydroceramide synthase activity was recovered in the digitoninsolubilized supernatant, which correlated with levels of LASS5-HA detected by Western blotting (Fig. 1A). Digitonin-solubilized LASS5-HA displayed the same fatty acid specificity as membranebound LASS5, showing an 10-fold higher activity toward palmitoyl-CoA than toward stearoyl-CoA (Fig. 1B), and was inhibited by the (dihydro)ceramide synthase inhibitor fumonisin B1 (16) to a similar extent as observed in the homogenate (Fig. 1B).

Digitonin-solubilized LASS5-HA was subsequently immunoprecipitated using an anti-HA agarose conjugate and eluted using 100 mM glycine. A significant fraction of the immunoprecipitated LASS5-HA could be eluted from the beads (Fig. 2A), and analysis by SDS-polyacrylamide gel electrophoresis revealed only one band, with a molecular mass of 48 kDa (Fig. 2B), similar to the predicted molecular mass of LASS5-HA. No other bands could be detected reproducibly either by silver staining of the gel (Fig. 2B) or by Coomassie staining (not shown). The identity of the band as LASS5-HA was confirmed by Western blotting (Fig. 2C) and by MALDI-TOF mass spectrometry (TABLE ONE). In addition, no other peptides co-migrated with LASS5 (TABLE ONE), which was confirmed by nano-liquid chromatography electrospray ionization tandem mass spectrometry (not shown).

View larger version (5K): [in this window] [in a new window]   FIGURE 1. Solubilization of LASS5-HA by digitonin. LASS5-HA activity was measured in a homogenate (Hom), a homogenate to which digitonin had been added (Dig), the digitonin-solubilized supernatant after centrifugation (Sup), the resuspended pellet (Pellet), and in a homogenate from pcDNA-HA-transfected cells (pcDNA). A, dihydroceramide synthase activity in each fraction analyzed using 1-[14C]palmitoyl-CoA. The insert above the graph shows a Western blot using a rabbit polyclonal anti-HA antibody in the same fractions. B, dihydroceramide synthase activity using 1-[14C]palmitoyl-CoA (filled bars)or 1-[14C]stearoyl-CoA (hatched bars). The insert shows the inhibition of dihydroceramide synthase activity with (hatched bars) or without (filled bars) fumonisin B1 (20 µm). Each set of data is from quadruplet analysis ± S.D. and is representative of 2–3 independent experiments, which gave similar results.

View larger version (5K): [in this window] [in a new window]   FIGURE 2. Immunoprecipitation of LASS5-HA. A, LASS5-HA was solubilized using digitonin, immunoprecipitated, eluted from the beads, and detected by Western blotting using a rabbit polyclonal anti-HA antibody. Hom, homogenate; Sol, digitonin-solubilized supernatant; pcDNA, homogenate of pcDNA-HA-transfected cells; IP, immunoprecipitated LASS5-HA after elution from the beads using SDS elution buffer; Eluate, LASS5-HA eluted using 100 mM glycine, pH 2.5. B, SDS-polyacrylamide gel electrophoresis of LASS5-HA eluted using 100 mM glycine and detected by silver staining. The position of molecular size markers is shown. The pcDNA lane is taken from an identical experiment but transfected using pcDNA-HA rather than LASS5-HA. This experiment was repeated four times, and in all cases, the identity of the band was confirmed by MALDI-TOF mass spectrometry (TABLE ONE) or by Western blotting (C) using the same antibody as in A.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
In the current study we have demonstrated that LASS5 is a bona fide (dihydro)ceramide synthase. This is the first time that a mammalian dihydroceramide synthase has been purified, representing one of the last recalcitrant enzymes in the SL biosynthetic pathway (5).

In contrast to yeast, in which SLs contain only one kind of fatty acid, namely C26, mammalian (dihydro)ceramides contain a wide fatty acid spectrum (2, 4). It was formerly assumed that this was due to a lack of specificity of dihydroceramide synthase with respect to the use of fattyacyl-CoAs. However, the discovery of a family of mammalian LASS genes that each synthesizes dihydroceramides containing different fatty acids (at least those characterized to date (8–10)) demonstrates that this is not the case. In contrast, yeast have only two highly homologous ceramide synthase genes, LAG1 and LAC1, which together are responsible for the synthesis of C₂₆-ceramides.

Evidence is accumulating that ceramides containing specific fatty acids are involved in defined cell functions in mammalian cells (2, 17). This being the case, it might be expected that individual LASS genes would be expressed in either a tissue-specific (9, 18) or temporal manner so as to supply specific ceramides for the distinct events in which they are involved. Our demonstration that LASS5 is a bona fide dihydroceramide synthase that selectively utilizes palmitoyl-CoA supports this likelihood and strengthens the hypothesis that specific LASS proteins play distinct roles either in ceramide signaling or in SL metabolism. Evidence for the latter has already been obtained by the observation that C₁₈-ceramide formed by LASS1 is selectively channeled into neutral glyco-SLs but not gangliosides. The availability of purified LASS5 will permit systematic characterization of the reaction mechanism and modes of regulation of a mammalian dihydroceramide synthase (19).

View larger version (4K): [in this window] [in a new window]   FIGURE 3. (Dihydro)ceramide synthase activity of purified LASS5. The dihydroceramide synthase activity of purified LASS5 was analyzed using 1-[14C]palmitoyl-CoA after no addition or addition of DOPC or DOPS upon elution from the beads (A) in the presence of DOPC using 1-[14C]palmitoyl-CoA (14C16-CoA) or 1-[14C]stearoyl-CoA (14C16-CoA)(B) and using 1-[14C]palmitoyl-CoA in the presence of DOPC and sphinganine (Sa) or sphingosine (So) with or without fumonisin B1 (FB1)(C). The area of the thin layer chromatography plate corresponding to ceramide is shown and is representative of 2–4 independent experiments, which gave similar results.

	FOOTNOTES

 
^* This work was supported by Israel Science Foundation Grant 1047/03. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Joseph Meyerhoff Professor of Biochemistry. To whom correspondence should be addressed: Dept. of Biological Chemistry, Weizmann Inst. of Science, Rehovot 76100, Israel. Tel.: 972-8-9342704; Fax: 972-8-9344112; E-mail: tony.futerman{at}weizmann.ac.il.

² The abbreviations used are: SL, sphingolipid; DOPC, dioleoylphosphatidylcholine;DOPS, dioleoylphosphatidylserine; HA, hemagglutinin; LASS5, longevity assurance gene 5; MALDI-TOF, matrix-assisted laser desorption/time of flight ionization.

³ We attempted to determine the extent of recovery and -fold purification of LASS5 from the digitonin-solubilized supernatant. However, because of the low amounts of purified LASS5 protein and the inherent difficulties in estimating the amount of protein after silver staining of the SDS-gel, we can only provide estimates of these values. In three separate experiments, the -fold increase in specific activity of the immunoprecipitated protein compared with the digitonin-solubilized supernatant varied between 5,000 and 12,000, and the recovery of LASS5 activity (toward 1-[¹⁴C]palmitoyl-CoA as substrate) varied between 26 and 49%. These values are probably underestimates because we have not systematically determined the conditions for optimal activity of purified LASS5.

	ACKNOWLEDGMENTS

 
We thank Christian Riebeling for the initial cloning of LASS5-HA, Howard Riezman and Beatrice Vallee for sharing unpublished data about the purification of yeast Lag1p/Lac1p/Lip1p, and Dr. Alla Shainskaya from the Mass Spectrometry Unit of the Weizmann Institute of Science for the MALDI-TOF analyses.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 

1. Hannun, Y. A., and Obeid, L. M. (2002) J. Biol. Chem. 277, 25847–25850[Free Full Text]
2. Futerman, A. H., and Hannun, Y. A. (2004) EMBO Rep. 5, 777–782[CrossRef][Medline] [Order article via Infotrieve]
3. Gulbins, E., and Kolesnick, R. (2003) Oncogene 22, 7070–7077[CrossRef][Medline] [Order article via Infotrieve]
4. Merrill, A. H., Jr. (2002) J. Biol. Chem. 277, 25843–25846[Free Full Text]
5. Futerman, A. H., and Riezman, H. (2005) Trends Cell Biol. 15, 312–318[CrossRef][Medline] [Order article via Infotrieve]
6. Venkataraman, K., and Futerman, A. (2002) FEBS Lett. 528, 3–4[CrossRef][Medline] [Order article via Infotrieve]
7. Winter, E., and Ponting, C. P. (2002) Trends Biochem. Sci. 27, 381–383[CrossRef][Medline] [Order article via Infotrieve]
8. Venkataraman, K., Riebeling, C., Bodennec, J., Riezman, H., Allegood, J. C., Sullards, M. C., Merrill, A. H., Jr., and Futerman, A. H. (2002) J. Biol. Chem. 277, 35642–35649[Abstract/Free Full Text]
9. Riebeling, C., Allegood, J. C., Wang, E., Merrill, A. H., Jr., and Futerman, A. H. (2003) J. Biol. Chem. 278, 43452–43459[Abstract/Free Full Text]
10. Mizutani, Y., Kihara, A., and Igarashi, Y. (2005) Biochem. J. 390, 263–271[CrossRef][Medline] [Order article via Infotrieve]
11. Bodennec, J., Pelled, D., Riebeling, C., Trajkovic, S., and Futerman, A. H. (2002) FASEB J. 16, 1814–1816[Abstract/Free Full Text]
12. Hirschberg, K., Rodger, J., and Futerman, A. H. (1993) Biochem. J. 290, 751–757[Medline] [Order article via Infotrieve]
13. Vallee, B., and Riezman, H. (2005) EMBO J. 24, 730–741[CrossRef][Medline] [Order article via Infotrieve]
14. Guillas, I., Kirchman, P. A., Chuard, R., Pfefferli, M., Jiang, J. C., Jazwinski, S. M., and Conzelmann, A. (2001) EMBO J. 20, 2655–2665[CrossRef][Medline] [Order article via Infotrieve]
15. Schorling, S., Vallee, B., Barz, W. P., Riezman, H., and Oesterhelt, D. (2001) Mol. Biol. Cell 12, 3417–3427[Abstract/Free Full Text]
16. Merrill, A. H., Liotta, D. C., and Riley, R. (1996) Trends Cell Biol. 6, 218–223[CrossRef][Medline] [Order article via Infotrieve]
17. Koybasi, S., Senkal, C. E., Sundararaj, K., Spassieva, S., Bielawski, J., Osta, W., Day, T. A., Jiang, J. C., Jazwinski, S. M., Hannun, Y. A., Obeid, L. M., and Ogretmen, B. (2004) J. Biol. Chem. 279, 44311–44319[Abstract/Free Full Text]
18. Xu, Z., Zhou, J., McCoy, D. M., and Mallampalli, R. K. (2005) J. Lipid Res. 46, 1229–1238[Abstract/Free Full Text]
19. Kok, J. W., Nikolova-Karakashian, M., Klappe, K., Alexander, C., and Merrill, A. H. (1997) J. Biol. Chem. 272, 21128–21136[Abstract/Free Full Text]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				S. Lahiri, H. Park, E. L. Laviad, X. Lu, R. Bittman, and A. H. Futerman Ceramide Synthesis Is Modulated by the Sphingosine Analog FTY720 via a Mixture of Uncompetitive and Noncompetitive Inhibition in an Acyl-CoA Chain Length-de pend ent Manner J. Biol. Chem., June 12, 2009; 284(24): 16090 - 16098. [Abstract] [Full Text] [PDF]

				M. Kyogashima, K. Tadano-Aritomi, T. Aoyama, A. Yusa, Y. Goto, K. Tamiya-Koizumi, H. Ito, T. Murate, R. Kannagi, and A. Hara Chemical and Apoptotic Properties of Hydroxy-Ceramides Containing Long-Chain Bases with Unusual Alkyl Chain Lengths J. Biochem., July 1, 2008; 144(1): 95 - 106. [Abstract] [Full Text] [PDF]

				M. Rabionet, A. C. van der Spoel, C.-C. Chuang, B. von Tumpling-Radosta, M. Litjens, D. Bouwmeester, C. C. Hellbusch, C. Korner, H. Wiegandt, K. Gorgas, et al. Male Germ Cells Require Polyenoic Sphingolipids with Complex Glycosylation for Completion of Meiosis: A LINK TO CERAMIDE SYNTHASE-3 J. Biol. Chem., May 9, 2008; 283(19): 13357 - 13369. [Abstract] [Full Text] [PDF]

				E. L. Laviad, L. Albee, I. Pankova-Kholmyansky, S. Epstein, H. Park, A. H. Merrill Jr., and A. H. Futerman Characterization of Ceramide Synthase 2: TISSUE DISTRIBUTION, SUBSTRATE SPECIFICITY, AND INHIBITION BY SPHINGOSINE 1-PHOSPHATE J. Biol. Chem., February 29, 2008; 283(9): 5677 - 5684. [Abstract] [Full Text] [PDF]

				A. Mesika, S. Ben-Dor, E. L. Laviad, and A. H. Futerman A New Functional Motif in Hox Domain-containing Ceramide Synthases: IDENTIFICATION OF A NOVEL REGION FLANKING THE Hox AND TLC DOMAINS ESSENTIAL FOR ACTIVITY J. Biol. Chem., September 14, 2007; 282(37): 27366 - 27373. [Abstract] [Full Text] [PDF]

				J. Min, A. Mesika, M. Sivaguru, P. P. Van Veldhoven, H. Alexander, A. H. Futerman, and S. Alexander (Dihydro)ceramide Synthase 1 Regulated Sensitivity to Cisplatin Is Associated with the Activation of p38 Mitogen-Activated Protein Kinase and Is Abrogated by Sphingosine Kinase 1 Mol. Cancer Res., August 1, 2007; 5(8): 801 - 812. [Abstract] [Full Text] [PDF]

				Y. Baran, A. Salas, C. E. Senkal, U. Gunduz, J. Bielawski, L. M. Obeid, and B. Ogretmen Alterations of Ceramide/Sphingosine 1-Phosphate Rheostat Involved in the Regulation of Resistance to Imatinib-induced Apoptosis in K562 Human Chronic Myeloid Leukemia Cells J. Biol. Chem., April 13, 2007; 282(15): 10922 - 10934. [Abstract] [Full Text] [PDF]

				C. E. Senkal, S. Ponnusamy, M. J. Rossi, J. Bialewski, D. Sinha, J. C. Jiang, S. M. Jazwinski, Y. A. Hannun, and B. Ogretmen Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas Mol. Cancer Ther., February 1, 2007; 6(2): 712 - 722. [Abstract] [Full Text] [PDF]

				K. Kitatani, J. Idkowiak-Baldys, J. Bielawski, T. A. Taha, R. W. Jenkins, C. E. Senkal, B. Ogretmen, L. M. Obeid, and Y. A. Hannun Protein Kinase C-induced Activation of a Ceramide/Protein Phosphatase 1 Pathway Leading to Dephosphorylation of p38 MAPK J. Biol. Chem., December 1, 2006; 281(48): 36793 - 36802. [Abstract] [Full Text] [PDF]

				S. Spassieva, J.-G. Seo, J. C. Jiang, J. Bielawski, F. Alvarez-Vasquez, S. M. Jazwinski, Y. A. Hannun, and L. M. Obeid Necessary Role for the Lag1p Motif in (Dihydro)ceramide Synthase Activity J. Biol. Chem., November 10, 2006; 281(45): 33931 - 33938. [Abstract] [Full Text] [PDF]

				Y. Pewzner-Jung, S. Ben-Dor, and A. H. Futerman When Do Lasses (Longevity Assurance Genes) Become CerS (Ceramide Synthases)?: INSIGHTS INTO THE REGULATION OF CERAMIDE SYNTHESIS J. Biol. Chem., September 1, 2006; 281(35): 25001 - 25005. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 280/40/33735    most recent M506485200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lahiri, S. Articles by Futerman, A. H. Search for Related Content PubMed PubMed Citation Articles by Lahiri, S. Articles by Futerman, A. H. Social Bookmarking                      What's this?